We are live on ! Find out more
RA

Rosalind Advisors Portfolio holdings

AUM $249M
1-Year Est. Return 80.12%
This Fund
S&P 500
This Quarter Est. Return
+28.8%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$196M
AUM Growth
+$39.4M
Cap. Flow
+$512M
Cap. Flow %
261.81%
Top 10 Hldgs %
65.77%
Holding
51
New
18
Increased
7
Reduced
11
Closed
11

Top Buys

Rank Stock Value
1
URGN icon
UroGen Pharma
URGN
+$10.4M
2
SVRA icon
Savara
SVRA
+$9.26M
3
FLNA
Filana Therapeutics
FLNA
+$7.33M
4
FENC icon
Fennec Pharmaceuticals
FENC
+$6.45M
5
CMRX
Chimerix, Inc.
CMRX
+$4.3M

Top Sells

Rank Stock Value
1
CRMD icon
CorMedix
CRMD
+$14.7M
2
CLRB icon
Cellectar Biosciences
CLRB
+$7.86M
3
VRNA
Verona Pharma
VRNA
+$4.69M
4
HELP
Cybin Inc
HELP
+$2.68M
5
OTLK icon
Outlook Therapeutics
OTLK
+$2.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCTH icon
1
Delcath Systems
DCTH
$416M
$31.9M 16.32%
2,650,389
– –
MYO icon
2
Myomo
MYO
$38.6M
$19.3M 9.88%
2,998,945
-22,446
-0.7% -$109K
MDWD icon
3
MediWound
MDWD
$181M
$11.2M 5.72%
628,050
– –
CMRX
4
DELISTED
Chimerix, Inc.
CMRX
$10.6M 5.43%
+3,050,000
New +$4.3M
XERS icon
5
Xeris Biopharma Holdings
XERS
$1.45B
$10.5M 5.38%
3,104,995
– –
ABEO icon
6
Abeona Therapeutics
ABEO
$369M
$10.1M 5.14%
1,805,390
-26,610
-1% -$164K
OCUL icon
7
Ocular Therapeutix
OCUL
$1.85B
$9.64M 4.93%
1,128,700
+243,700
+28% +$2.38M
URGN icon
8
UroGen Pharma
URGN
$2B
$9.27M 4.74%
+870,000
New +$10.4M
SVRA icon
9
Savara
SVRA
$1.14B
$8.15M 4.17%
+2,654,944
New +$9.26M
FENC icon
10
Fennec Pharmaceuticals
FENC
$344M
$7.96M 4.07%
+1,259,876
New +$6.45M
HELP
11
Cybin Inc
HELP
$505M
$7.15M 3.66%
810,918
-264,187
-25% -$2.68M
VRNA
12
DELISTED
Verona Pharma
VRNA
$6.97M 3.56%
150,000
-125,000
-45% -$4.69M
NSPR icon
13
InspireMD
NSPR
$31.5M
$6.56M 3.36%
2,495,783
-18,263
-0.7% -$49.1K
OPTN
14
DELISTED
OptiNose
OPTN
$5.86M 3%
876,996
+324,496
+59% +$2.86M
PROF
15
Profound Medical
PROF
$263M
$5.2M 2.66%
692,185
+206,212
+42% +$1.58M
VSTM icon
16
Verastem
VSTM
$536M
$4.65M 2.38%
+900,000
New +$3.54M
TRVI icon
17
Trevi Therapeutics
TRVI
$2.61B
$4.38M 2.24%
1,062,500
+312,500
+42% +$1M
FLNA
18
PUT
Filana Therapeutics
FLNA
$46.4M
$3.65M 1.87%
417,400
+50,000
+14% +$878K
REPL icon
19
Replimune Group
REPL
$455M
$3.15M 1.61%
+260,000
New +$3.16M
PYPD icon
20
PolyPid
PYPD
$83.8M
$3.09M 1.58%
1,018,021
+338,853
+50% +$1.11M
BMEA icon
21
PUT
Biomea Fusion
BMEA
$88.2M
$2.76M 1.41%
+910,700
New +$7.26M
CMPS
22
Compass Pathways
CMPS
$1.56B
$2.67M 1.37%
707,625
-73,798
-9% -$374K
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
$2.57M 1.32%
303,864
– –
ACOG
24
Alpha Cognition
ACOG
$190M
$1.49M 0.76%
+252,753
New +$1.42M
FLNA
25
Filana Therapeutics
FLNA
$46.4M
$985K 0.5%
+417,400
New +$7.33M
1
2 3

Similar funds

TAM
Tabor Asset Management New York $249M AUM 48.59% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
MC
Mount Capital London, United Kingdom $248M AUM 4.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
GWS
Greykasell Wealth Strategies Danville, California $248M AUM 22.08% 1-Year Est. Return
SCM
Segra Capital Management Palm Beach, Florida $248M AUM 65.61% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return

Rosalind Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Rosalind Advisors held 51 positions worth $196M, up 25% from $156M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Rosalind Advisors deployed $512M of net new capital in Q4 2024, opening 18 new positions and adding to 7 existing holdings. Its largest new stake was UroGen Pharma: 870,000 shares worth $9.27M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier.

On the sell side, the largest reduction was Verona Pharma, an estimated $4.69M trimmed.

  • Rosalind Advisors's largest Q4 2024 buy was UroGen Pharma: 870,000 shares worth $9.27M.
  • Rosalind Advisors added most to OptiNose in Q4 2024, an estimated $2.86M increase.
  • Rosalind Advisors's biggest Q4 2024 reduction was Verona Pharma, cutting an estimated $4.69M.
  • Rosalind Advisors fully exited CorMedix in Q4 2024, selling an estimated $14.7M.
  • Rosalind Advisors's ten largest holdings make up 66% of its $196M portfolio in Q4 2024.
  • Rosalind Advisors opened 18 new positions and closed 11 in Q4 2024.
  • Rosalind Advisors's portfolio value rose 25% quarter-over-quarter to $196M.

Based on Rosalind Advisors's 13F filing for Q4 2024, filed 11 Feb 2025.